The response to TKIs in a subset of patients with NSCLC, whose tumors express EGFR carrying activating mutations, has been excellent but short-lived due to the inevitable evolution of cancer cells to acquire secondary resistance mutations, preventing the binding of TKIs to EGFR. Here, EGFR is linked to cancer.